


Edited by
Yogeshwar Bachhav

Innovative Dosage Forms

Design and Development
at Early Stage

Volume 76

Series Editors:
R. Mannhold,
H. Buschmann, J. Holenz



Innovative Dosage Forms

Methods and Principles in Medicinal Chemistry

Edited by R. Mannhold, H. Buschmann, Jörg Holenz

Editorial Board

G. Folkerts, H. Kubinyi, H. Timmerman, H. van de Waterbeemd, J. Bondon-Hansen

Previous Volumes of this Series:

Gervasio, F. L., Spiwok, V. (Eds.)

Biomolecular Simulations in Structure-based Drug Discovery

2018

ISBN: 978-3-527-34265-5

Vol. 75

Sippl, W., Jung, M. (Eds.)

Epigenetic Drug Discovery

2018

ISBN: 978-3-527-34314-0

Vol. 74

Giordanetto, F. (Ed.)

Early Drug Development

2018

ISBN: 978-3-527-34149-8

Vol. 73

Handler, N., Buschmann, H. (Eds.)

Drug Selectivity

2017

ISBN: 978-3-527-33538-1

Vol. 72

Vaughan, T., Osbourn, J., Jalla, B. (Eds.)

Protein Therapeutics

2017

ISBN: 978-3-527-34086-6

Vol. 71

Ecker, G. F., Clausen, R. P., and Sitte, H. H.
(Eds.)

Transporters as Drug Targets

2017

ISBN: 978-3-527-33384-4

Vol. 70

Martic-Kehl, M. I., Schubiger, P.A. (Eds.)

Animal Models for Human Cancer

**Discovery and Development of Novel
Therapeutics**

2017

ISBN: 978-3-527-33997-6

Vol. 69

Holenz, Jörg (Ed.)

Lead Generation

Methods and Strategies

2016

ISBN: 978-3-527-33329-5

Vol. 68

Innovative Dosage Forms

Design and Development at Early Stage

Edited by Yogeshwar G. Bachhav

WILEY-VCH

Series Editors

Dr. Raimund Mannhold

Rosenweg 7
40489 Düsseldorf
Germany

Dr. Helmut Buschmann

Aachen, Germany
Sperberweg 15
52076 Aachen
Germany

Dr. Jörg Holenz

GSK
R&D Neurosciences TAU
1250 S. Collegeville Road, PA
United States

Volume Editor

Dr. Yogeshwar G. Bachhav

Adex Pharmaceutical Consultancy
Services, C-201
Bharatkhand CHS
Tilaknagar, Chembur
400089 Mumbai
India

■ All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.:
applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-34396-6

ePDF ISBN: 978-3-527-81220-2

ePub ISBN: 978-3-527-81218-9

oBook ISBN: 978-3-527-81217-2

Cover Design SCHULZ Grafik-Design,
Fußgönheim, Germany

Typesetting SPi Global, Chennai, India

Printing and Binding

Printed on acid-free paper

10 9 8 7 6 5 4 3 2 1

Contents

Preface *xvii*

| | | |
|----------|---|----------|
| 1 | Impact of the Polymorphic Form of Drugs/NCEs on Preformulation and Formulation Development | 1 |
| | <i>MHD Bashir Alsirawan and Anant Paradkar</i> | |
| 1.1 | Introduction | 1 |
| 1.1.1 | Background | 1 |
| 1.1.2 | Types of Polymorphism | 2 |
| 1.1.2.1 | Conformational Polymorphism | 2 |
| 1.1.2.2 | Packing Polymorphism | 4 |
| 1.1.3 | Thermodynamic-Based Classification of Polymorphism | 4 |
| 1.1.3.1 | Enantiotropic Polymorphism | 4 |
| 1.1.3.2 | Monotropic Polymorphism | 5 |
| 1.1.4 | Concomitant Polymorphism | 6 |
| 1.1.5 | Debatable Polymorphism Cases | 7 |
| 1.1.5.1 | Tautomeric Polymorphism or Tautomerism | 7 |
| 1.1.5.2 | Enantiomerism/Stereoisomerism | 7 |
| 1.1.5.3 | Pseudopolymorphism | 8 |
| 1.2 | Polymorphism Impact on Drug/Excipient Properties | 9 |
| 1.2.1 | Physicochemical Properties | 10 |
| 1.2.2 | Mechanical Properties | 11 |
| 1.2.3 | Impact of Polymorphism on <i>In Vivo</i> Performance | 13 |
| 1.2.3.1 | Effect of Polymorphism on Solubility | 14 |
| 1.2.3.2 | Effect of Polymorphism on Dissolution Rate/Solubility Kinetics | 17 |
| 1.2.3.3 | Effect of Polymorphism on Bioavailability | 20 |
| 1.3 | Critical Impact of Polymorphic Form of API on Processing and Formulation | 22 |
| 1.3.1 | Process-induced Transformation Types | 23 |
| 1.3.1.1 | Grinding-induced Transitions | 23 |
| 1.3.1.2 | Granulation-induced Transitions | 25 |
| 1.3.1.3 | Tableting-induced Transition | 30 |
| 1.3.1.4 | Freeze-drying-induced Transition | 32 |
| 1.3.1.5 | Spray-drying-induced Transitions | 33 |
| 1.3.1.6 | Supercritical-fluid-induced Transitions | 35 |
| 1.4 | Conclusion | 37 |
| | References | 38 |

| | | |
|----------|--|-----------|
| 2 | Strategies for the Formulation Development of Poorly Soluble Drugs via Oral Route | 49 |
| | <i>Sanket Shah, Abhijit Date, and Renè Holm</i> | |
| 2.1 | Introduction | 50 |
| 2.2 | Quality by Testing (QbT) and Quality by Design (QbD) | 50 |
| 2.3 | Linking the Formulation to the Clinical Phase | 52 |
| 2.4 | Defining the Formulation Strategy | 55 |
| 2.5 | Nanosuspensions | 58 |
| 2.5.1 | Description | 58 |
| 2.5.2 | Method of Manufacturing | 59 |
| 2.5.2.1 | Top-Down Methods | 59 |
| 2.5.2.2 | Wet Media Milling Technology | 60 |
| 2.5.2.3 | High-pressure Homogenization | 61 |
| 2.5.2.4 | Bottom-Up Methods | 62 |
| 2.5.2.5 | Methods Utilizing a Hybrid Approach | 63 |
| 2.5.3 | Characterization of Nanosuspensions | 63 |
| 2.5.3.1 | Particle Size, Polydispersity Index, and Particle Morphology | 63 |
| 2.5.3.2 | Surface Charge | 63 |
| 2.5.3.3 | Particle Morphology | 64 |
| 2.5.3.4 | Solid-state Properties | 64 |
| 2.5.3.5 | Saturation Solubility and Dissolution Velocity | 64 |
| 2.6 | Solid Dispersion | 64 |
| 2.6.1 | Description | 65 |
| 2.6.2 | Method of Manufacturing | 66 |
| 2.6.2.1 | Melting/Fusion | 66 |
| 2.6.2.2 | Solvent Evaporation | 67 |
| 2.6.2.3 | Coprecipitation | 67 |
| 2.6.3 | Characterization | 68 |
| 2.6.3.1 | Investigation of Crystallinity | 68 |
| 2.6.3.2 | Investigation of Molecular Arrangement | 69 |
| 2.7 | Lipid-Based Drug Delivery Systems | 69 |
| 2.7.1 | Description | 70 |
| 2.7.2 | Method of Manufacture | 71 |
| 2.7.3 | Characterization | 75 |
| 2.7.4 | Role of API Property on Lipid-Based DDS | 76 |
| 2.8 | Micellar System | 76 |
| 2.8.1 | Description | 76 |
| 2.8.2 | Formulation Development and Optimization | 80 |
| 2.8.3 | Characterization | 81 |
| 2.9 | Mesoporous Silica Particles | 81 |
| 2.9.1 | Description | 82 |
| 2.9.2 | Method of Manufacturing and Characterization | 83 |
| 2.9.3 | Case Study on the <i>in Vivo</i> Efficacy of Mesoporous Silica Particles | 84 |
| 2.10 | Conclusion | 84 |
| | References | 85 |

| | | |
|----------|---|------------|
| 3 | Effect of Residual Reactive Impurities in Excipients on the Stability of Pharmaceutical Products | 91 |
| | <i>Ankit Sharma</i> | |
| 3.1 | Introduction | 91 |
| 3.2 | Reactive Impurities in the Excipients and Their Impact on Drug Stability | 92 |
| 3.3 | Impact of Reactive Impurities on Drug–Excipient Compatibility | 93 |
| 3.3.1 | Physical Interactions | 93 |
| 3.3.2 | Chemical Interactions | 94 |
| 3.3.3 | Oxidative Degradation | 94 |
| 3.3.4 | Peroxides | 95 |
| 3.3.5 | Transition Metal Impurities | 96 |
| 3.3.6 | Condensation Reactions | 99 |
| 3.3.7 | Aldehyde Impurities | 99 |
| 3.3.8 | Reducing Sugars | 102 |
| 3.3.9 | Organic Acids | 103 |
| 3.3.10 | Hydrolytic Degradation | 105 |
| 3.4 | Risk Assessment for API Incompatibilities and Mitigation Strategies | 107 |
| 3.5 | Assessment of Incompatibilities of API with Excipients | 108 |
| 3.6 | Design and Selection of Drug Substance | 109 |
| 3.7 | Formulation Strategies to Circumvent API Degradation | 110 |
| 3.8 | Inhibition of Oxidative Degradation | 110 |
| 3.8.1 | Initiation Inhibitors | 111 |
| 3.8.2 | Propagation Inhibitors | 111 |
| 3.8.3 | Selection of Antioxidant | 112 |
| 3.9 | Super-Refined Excipients | 113 |
| 3.9.1 | Polyethylene Glycols (PEG) | 114 |
| 3.9.2 | Polysorbates | 114 |
| 3.9.3 | Fatty Acids | 115 |
| 3.10 | Packaging and Storage | 115 |
| 3.11 | Concluding Remarks | 116 |
| | References | 116 |
| 4 | Preclinical Formulation Assessment of NCEs | 119 |
| | <i>Raju Saka, Priyadarshini Sathe, Wahid Khan, and Sachin Dubey</i> | |
| 4.1 | Introduction | 120 |
| 4.2 | Significance of Various Properties of NCEs in Early Drug Discovery | 122 |
| 4.2.1 | Solubility | 123 |
| 4.2.2 | Permeability | 124 |
| 4.2.3 | Stability | 125 |
| 4.3 | Formulation Strategies to Improve Properties of NCEs | 125 |
| 4.3.1 | pH Modification | 127 |
| 4.3.2 | Cosolvents | 127 |

| | | |
|---------|---|-----|
| 4.3.3 | Cyclodextrins | 128 |
| 4.3.4 | Surfactants | 128 |
| 4.3.5 | Suspensions and Nanosuspensions | 129 |
| 4.3.6 | Emulsions and Microemulsions | 130 |
| 4.3.7 | Solid Dispersions | 130 |
| 4.3.8 | Liposomes | 131 |
| 4.4 | Preclinical Formulation Assessment of Oral, Parenteral, and Topical Dosage Forms | 131 |
| 4.4.1 | Oral Formulations | 131 |
| 4.4.1.1 | Formulation Development | 132 |
| 4.4.2 | Parenteral Formulations | 134 |
| 4.4.3 | Topical Formulations | 135 |
| 4.4.3.1 | Structure of Skin and Effect on Permeation | 136 |
| 4.4.3.2 | Formulation Effect | 136 |
| 4.4.3.3 | Skin Metabolism | 136 |
| 4.4.3.4 | Formulation Development | 136 |
| 4.4.3.5 | Formulation Approaches | 137 |
| 4.4.4 | Excipients | 138 |
| 4.4.5 | Characterization and Stability of Preclinical Formulations | 140 |
| 4.4.6 | Formulation Selection for Pharmacokinetic Studies | 141 |
| 4.4.7 | Formulation Selection for Pharmacodynamic Studies | 142 |
| 4.4.8 | Formulation Development for Toxicity Studies | 142 |
| 4.5 | Case Studies | 143 |
| 4.5.1 | Case 1: Use of Surfactant to Prevent Precipitation of API in Cosolvent-Based Formulations | 143 |
| 4.5.2 | Case 2: Topical Gel Microemulsion Formulation of Lipophilic Drug WHI-07 | 144 |
| 4.5.3 | Case 3: Salt Approach to Improve the Bioavailability of the Poorly Soluble Drug | 144 |
| 4.5.4 | Case 4: Use of SMEDDS Dosage Form to Improve Bioavailability | 145 |
| 4.5.5 | Case 5: Micronized Suspension of Poorly Soluble Lead Compounds Using Wet Milling Technique | 145 |
| 4.5.6 | Case 6: Polymer Addition in Cyclodextrin-Based Formulations and pH Adjustment | 146 |
| 4.5.7 | Case 7: Cyclodextrin Complexation to Improve Topical Delivery of a Poorly Soluble Compound | 146 |
| 4.5.8 | Case 8: Use of Solublizers and Their Effect on PK of Preclinical Lead Candidates | 147 |
| 4.5.9 | Case 9: Self-nanoemulsifying Drug Delivery Systems (SNEDDS) to Improve Solubility and Bioavailability | 147 |
| 4.6 | Conclusion and Future Perspectives | 148 |
| | References | 148 |
| 5 | Regulatory Aspects for Formulation Design – with Focus on the Solid State | 155 |
| | <i>Michael Gruss</i> | |
| 5.1 | The Understanding of “Regulatory” | 156 |
| 5.2 | Formulation Design | 157 |

| | | |
|---------|--|-----|
| 5.3 | An Extended Timescale | 158 |
| 5.4 | Solubility Data | 158 |
| 5.5 | Impact of Solubility and Dissolution Rate on Formulation Design | 162 |
| 5.6 | Single and Multicomponent Systems | 163 |
| 5.6.1 | Introduction | 163 |
| 5.6.2 | Scientific Point of View | 164 |
| 5.6.2.1 | Polymorphism | 164 |
| 5.6.2.2 | Polyamorphism | 165 |
| 5.6.2.3 | Multicomponent Compounds – Salt, Co-crystal, Solvate, and Hydrate | 165 |
| 5.6.3 | Fate and Pathway of a Compound During Development | 166 |
| 5.6.4 | Regulatory Point of View | 167 |
| 5.6.4.1 | Patents | 167 |
| 5.6.4.2 | Pharmacopeias | 168 |
| 5.7 | Analytical Techniques for the Characterization of the Solid State | 168 |
| 5.7.1 | Scientific Literature | 168 |
| 5.7.2 | Pharmacopeias | 169 |
| 5.8 | Control of Solid-state Constitution | 171 |
| 5.8.1 | The Process – from Synthesis to Patient | 171 |
| 5.8.2 | Change of Properties and Constitution | 173 |
| 5.8.3 | Need for Control of Solid-State Properties During the Process and Supply Chain | 173 |
| 5.9 | Regulatory Consideration of Solid Compounds | 174 |
| 5.9.1 | Definitions for Solid Compounds | 174 |
| 5.9.1.1 | Co-crystals and Solvates | 174 |
| 5.9.1.2 | Salts and Co-crystals | 174 |
| 5.9.1.3 | Polymorphism | 175 |
| 5.9.2 | Common Technical Document (CTD) – M4Q | 175 |
| 5.9.2.1 | CTD – Section 3.2.S – Drug Substance | 175 |
| 5.9.2.2 | CTD – Section 3.2.P – Drug Product | 177 |
| 5.9.3 | Guideline on the Chemistry of Active Substances | 178 |
| 5.9.4 | Guideline on Quality of Transdermal Patches | 180 |
| 5.9.5 | Quality Guidelines | 181 |
| 5.9.5.1 | ICH Q1A (R2) Stability Testing of New Drug Substances and Products | 182 |
| 5.9.5.2 | ICH Q1B Photostability Testing | 182 |
| 5.9.5.3 | ICH Q1C Stability Testing: Requirements for New Dosage Forms | 183 |
| 5.9.5.4 | ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances | 183 |
| 5.9.6 | EMA – Consideration and Perspective | 188 |
| 5.9.6.1 | Abridged Applications | 188 |
| 5.9.6.2 | New Active Substance (NAS) Status | 188 |
| 5.9.6.3 | Marketing Authorization Application (MAA) | 189 |
| 5.9.6.4 | Co-crystals and GMP Manufacturing | 189 |
| 5.9.6.5 | Active Substance Master File (ASMF) | 190 |
| 5.9.6.6 | Pharmaceutical Acceptance | 190 |
| 5.9.6.7 | Compounds Containing More than One Therapeutic Moiety | 190 |

| | | |
|---------|---|-----|
| 5.9.7 | FDA – Consideration and Perspective | 190 |
| 5.9.7.1 | Sources for Information | 190 |
| 5.9.7.2 | Naming of Drug Substances and Drug Products | 191 |
| 5.9.7.3 | Investigational New Drug Application (IND) | 192 |
| 5.9.7.4 | Marketing Authorization Application – New Drug Application (NDA) | 194 |
| 5.9.7.5 | ANDA – Abbreviated New Drug Applications | 194 |
| 5.9.7.6 | Regulatory Classification of Pharmaceutical Co-crystals and Salts | 196 |
| 5.9.8 | Similarities and Differences Between the Regulative Systems in the EU and United States | 197 |
| 5.10 | Conclusions and Recommendations | 198 |
| | Disclaimer | 198 |
| | References | 198 |

6 Insight into Innovative Applications of Parenteral Formulations

Clara Fernandes

| | | |
|---------|---|-----|
| 6.1 | Introduction | 209 |
| 6.2 | Factors Affecting Development of Sustained-/Controlled-Release Formulations | 209 |
| 6.3 | Overview of Sustained and Controlled Release Parenteral Formulations | 213 |
| 6.3.1 | Suspension Based Formulations | 213 |
| 6.3.1.1 | Nanosuspension Based Formulations | 213 |
| 6.3.1.2 | Microsuspension Based Formulations | 214 |
| 6.3.2 | Particulate System Based Formulations | 215 |
| 6.3.2.1 | Polymer Nanoparticles Based Formulations | 215 |
| 6.3.2.2 | Lipid Nanoparticles Based Formulations | 217 |
| 6.3.2.3 | Inorganic Nanoparticles Based Nanoparticles | 217 |
| 6.4 | Case Studies | 219 |
| 6.4.1 | Nanosuspension Formulation of Paclitaxel – Abraxane® | 219 |
| 6.4.2 | PLGA Depot Based Formulation of Triptorelin – Trelstar® | 219 |
| 6.4.3 | Microemulsion Formulation of Propofol | 220 |
| 6.4.4 | Inorganic Metal Nanoparticle Based Formulation for Parenteral Applications | 220 |
| 6.4.5 | Polymeric Formulation of Glatiramer | 221 |
| 6.5 | Conclusion | 222 |
| 6.6 | Future Prospects | 222 |
| | References | 222 |

7 Assessing Pharmacokinetics of Various Dosage Forms at Early Stage

Susanne Bonsmann and Joachim Ossig

| | | |
|-----|--------------------------------|-----|
| 7.1 | Introduction | 227 |
| 7.2 | Definition of Pharmacokinetics | 229 |

| | | |
|----------|---|------------|
| 7.2.1 | ADME Parameters | 229 |
| 7.2.1.1 | Absorption | 229 |
| 7.2.1.2 | Distribution | 230 |
| 7.2.1.3 | Metabolism and Excretion | 231 |
| 7.2.2 | Pharmacokinetic Parameters | 231 |
| 7.2.2.1 | Plasma Concentration Time Profile | 231 |
| 7.2.2.2 | Area Under the Curve (AUC) | 232 |
| 7.2.2.3 | Bioavailability (BA) | 233 |
| 7.2.2.4 | Volume of Distribution (V_d) | 234 |
| 7.2.2.5 | Clearance (Cl) | 234 |
| 7.2.2.6 | Half-life ($T_{1/2}$) | 235 |
| 7.2.3 | PK Studies During Drug Development | 236 |
| 7.2.3.1 | ADME <i>in Vitro</i> Studies | 236 |
| 7.2.3.2 | <i>In Vitro</i> Models | 237 |
| 7.2.3.3 | <i>In Vivo</i> Studies | 238 |
| 7.3 | Case Studies | 241 |
| 7.3.1 | Case Study 1 | 241 |
| 7.3.2 | Case Study 2 | 241 |
| 7.3.3 | Case Study 3 | 242 |
| 7.3.4 | Case Study 4 | 243 |
| 7.4 | Summary | 243 |
| | References | 243 |
| 8 | Transdermal Medical Devices: Formulation Aspects | 245 |
| | <i>Mayank Singhal, César E. S. Jimenez, Maria Lapteva, and Yogeshvar N. Kalia</i> | |
| 8.1 | Introduction | 246 |
| 8.2 | Microneedles | 247 |
| 8.2.1 | Delivery Using Solid Microneedles: Skin Pretreatment | 248 |
| 8.2.1.1 | Delivery of Low-Molecular-Weight Compounds | 248 |
| 8.2.1.2 | Delivery of High-Molecular-Weight Compounds | 251 |
| 8.2.2 | Delivery Using Coated Microneedles | 252 |
| 8.2.2.1 | Delivery of Low-Molecular-Weight Compounds | 252 |
| 8.2.2.2 | Delivery of High-Molecular-Weight Compounds: Formulation Challenges Related to the Formulation of Coated Microneedles – A Case Study | 252 |
| 8.2.3 | Delivery Using Dissolvable Microneedles | 254 |
| 8.2.3.1 | Delivery of Low-Molecular-Weight Compounds | 254 |
| 8.2.3.2 | Delivery of High-Molecular-Weight Compounds: Formulation Challenges Related to the Formulation of Dissolvable Microneedles – A Case Study | 255 |
| 8.2.4 | Delivery Using Hollow Microneedles | 255 |
| 8.2.4.1 | Delivery of Low-Molecular-Weight Compounds | 255 |
| 8.2.4.2 | Delivery of High-Molecular-Weight Compounds | 256 |
| 8.2.5 | Delivery of Vaccines | 257 |
| 8.2.6 | Modalities of Microneedle Use | 259 |
| 8.2.7 | Perspectives in Microneedle-Mediated Transdermal Delivery | 259 |
| 8.3 | Laser-Assisted Ablation: Skin Pretreatment | 260 |

| | | |
|-------|---|-----|
| 8.3.1 | Laser–Skin Interaction | 261 |
| 8.3.2 | Formulation Aspects | 262 |
| 8.3.3 | Perspective | 263 |
| 8.4 | Iontophoresis | 263 |
| 8.4.1 | Clinical Benefits of Iontophoresis in Transdermal/Topical Delivery | 264 |
| 8.4.2 | Selection of Drug Candidates | 265 |
| 8.4.3 | Iontophoretic Device Formulation Characteristics: Compositions and Challenges | 265 |
| 8.4.4 | Earlier Approved Commercial Devices | 266 |
| 8.4.5 | Smart Ionto System Features | 268 |
| 8.4.6 | Perspectives | 269 |
| | References | 269 |

9 Physical Characterization Techniques to Access Amorphous Nature 281

Aniket Sabnis, Niten Jadav, Tim Gough, Adrian Kelly, and Anant Paradkar

| | | |
|---------|--|-----|
| 9.1 | Introduction | 282 |
| 9.1.1 | Limitations of the Amorphous Form | 285 |
| 9.1.2 | Stabilization of the Amorphous Form | 285 |
| 9.1.3 | Solid Dispersion | 285 |
| 9.1.4 | Factors Affecting Solubility of API in the Form of Solid Dispersions | 287 |
| 9.1.5 | Limitations | 289 |
| 9.1.6 | Co-Amorphous | 289 |
| 9.2 | Screening Techniques for Amorphization | 290 |
| 9.2.1 | Amorphization: Solution-Based Techniques | 291 |
| 9.2.1.1 | Melting and Quench Cooling | 291 |
| 9.2.1.2 | Spray-Drying | 292 |
| 9.2.1.3 | Freeze-Drying | 293 |
| 9.2.1.4 | Flash Evaporation/Rotary Evaporation | 294 |
| 9.2.1.5 | Supercritical Fluid Processing | 294 |
| 9.2.2 | Amorphization: Solid-State Techniques | 294 |
| 9.2.2.1 | Dehydration of Crystalline Hydrates | 294 |
| 9.2.2.2 | Milling | 294 |
| 9.2.2.3 | Vacuum Compression Molding | 296 |
| 9.2.2.4 | Hot Melt Extrusion | 296 |
| 9.3 | Characterization of Amorphous Materials | 298 |
| 9.3.1 | X-Ray Powder Diffraction (XRPD) | 299 |
| 9.3.2 | Thermal Methods | 302 |
| 9.3.2.1 | Differential Scanning Calorimetry | 302 |
| 9.3.2.2 | Dynamic Mechanical Thermal Analysis | 305 |
| 9.3.3 | Perfusion/Solution Calorimetry | 307 |
| 9.3.4 | Density Measurements | 310 |
| 9.3.5 | Sorption Technique: Dynamic Vapor Sorption (DVS) | 310 |
| 9.3.6 | Vibrational Spectroscopy | 312 |
| 9.3.6.1 | Mid-Infrared Spectroscopy | 313 |

| | | |
|-----------|--|------------|
| 9.3.6.2 | Raman Spectroscopy | 316 |
| 9.3.6.3 | Near-Infrared Spectroscopy | 318 |
| 9.3.6.4 | Terahertz Spectroscopy | 319 |
| 9.4 | Summary | 321 |
| 9.5 | Future Prospects | 322 |
| | References | 323 |
| 10 | Design and Development of Ocular Formulations for Preclinical and Clinical Trials | 331 |
| | <i>Mathieu Schmitt</i> | |
| 10.1 | Introduction | 331 |
| 10.2 | Ocular Anatomy and Physiology | 332 |
| 10.3 | Ocular Routes of Administration | 336 |
| 10.4 | Drug Discovery in Ophthalmology | 337 |
| 10.4.1 | Repositioning of Existing Drugs from Other Disease Area | 337 |
| 10.4.2 | Optimization of Compound Class to Enhance Selectivity, Tolerance Profile, and Efficacy | 338 |
| 10.4.3 | Specific Development | 339 |
| 10.5 | Topical Drug Administration | 340 |
| 10.5.1 | Ocular Bioavailability | 340 |
| 10.5.2 | Drug Design | 340 |
| 10.5.3 | Prodrugs | 342 |
| 10.5.4 | Physiological Factors | 343 |
| 10.5.5 | Formulation and Drug Delivery Systems | 344 |
| 10.5.5.1 | <i>In Situ</i> Gelling Systems | 344 |
| 10.5.5.2 | Emulsion | 346 |
| 10.5.5.3 | Nonaqueous Solutions | 347 |
| 10.5.5.4 | Polymeric Micelles and Dendrimers | 348 |
| 10.5.5.5 | Cyclodextrins | 349 |
| 10.5.5.6 | Multiparticulate Drug Delivery Systems | 351 |
| 10.5.5.7 | Sustained-release Strategies for Anterior Segment | 352 |
| 10.5.6 | Patient Compliance Through Packaging | 354 |
| 10.6 | Posterior Segment Delivery | 356 |
| 10.6.1 | <i>In Situ</i> Depot | 357 |
| 10.6.2 | Prodrugs | 357 |
| 10.6.3 | Intraocular Implants/Microparticles | 358 |
| 10.7 | Conclusion | 360 |
| | References | 361 |
| 11 | Preclinical Safety Aspects for Excipients: Oral, IV, and Topical Routes | 367 |
| | <i>Florian Engel</i> | |
| 11.1 | Introduction | 368 |
| 11.2 | General Considerations | 369 |
| 11.3 | Undesired Side Effects of Excipients | 370 |
| 11.4 | Novel Excipients | 371 |
| 11.4.1 | Regulatory Requirements | 372 |

| | | |
|-----------|--|------------|
| 11.5 | Rationale in Selecting an Excipient | 375 |
| 11.5.1 | Data Sources | 376 |
| 11.5.1.1 | Inactive Ingredient Database (IID) | 376 |
| 11.5.1.2 | Pharmacopoeias | 376 |
| 11.5.1.3 | Generally Recognized as Safe (GRAS) | 376 |
| 11.5.1.4 | Handbook of Pharmaceutical Excipients | 377 |
| 11.5.1.5 | STEP Database | 377 |
| 11.5.1.6 | Other Databases | 377 |
| 11.5.1.7 | <i>In Silico</i> | 378 |
| 11.5.2 | Strategies to Determine “Estimated Safe Excipient Doses” | 378 |
| 11.5.3 | Special Considerations for Oral Use | 381 |
| 11.5.4 | Special Considerations for Intravenous Use | 381 |
| 11.5.5 | Special Considerations for Topical Use | 385 |
| 11.6 | Conclusions | 386 |
| | References | 387 |
| 12 | Formulation of Therapeutic Proteins: Strategies for Developing Oral Protein Formulations | 391 |
| | <i>Saurabh Patil, Aditya Narvekar, Amita Puranik, Ratnesh Jain, and Prajakta Dandekar</i> | |
| 12.1 | Introduction | 392 |
| 12.1.1 | Use of Proteins for Different Therapeutic Indications | 392 |
| 12.1.2 | Importance of Physicochemical Properties on Preformulation and Formulation Development of Protein Therapeutics | 394 |
| 12.1.3 | Stability Constraints and Formulation Challenges | 395 |
| 12.1.4 | Current Market Status and Opportunities of Therapeutic Proteins | 396 |
| 12.1.5 | Current Technologies for Protein Formulation Development | 398 |
| 12.1.6 | Current Approaches in Oral Delivery of Proteins for Enhanced GIT Absorption | 400 |
| 12.2 | Types of Proteins Used in Therapeutic Indications | 400 |
| 12.3 | Important Physicochemical Properties of Proteins for Formulation Development | 402 |
| 12.4 | Existing Route of Administrations of Protein Formulations | 404 |
| 12.5 | Developmental Aspects of Oral Protein Formulations | 405 |
| 12.5.1 | Resource Requirements for Manufacturing of Protein-Based Formulations | 406 |
| 12.5.2 | Stability Concerns of Proteins in the Gastrointestinal Tract (GIT) | 407 |
| 12.5.3 | Physical Barriers to Delivering Proteins and Peptides | 407 |
| 12.5.3.1 | Unstirred Layer of Intestinal Fluid | 407 |
| 12.5.3.2 | Epithelial Cell Membrane | 407 |
| 12.5.3.3 | Biochemical Barriers to Proteins and Peptides | 409 |
| 12.5.4 | Formulation Strategies for the Oral Delivery of Proteins and Peptides | 409 |
| 12.5.4.1 | Peptidase/Enzyme Inhibition Approaches | 409 |
| 12.5.4.2 | Use of Permeation Enhancers | 410 |
| 12.5.5 | Modification of the Physicochemical Properties | 411 |

| | | |
|----------|---|-----|
| 12.5.5.1 | PEGylation | 411 |
| 12.5.5.2 | Alteration of Amino Acids | 412 |
| 12.5.5.3 | Hydrophobization | 412 |
| 12.5.6 | Use of Particulate Formulations | 412 |
| 12.5.6.1 | Microemulsions | 413 |
| 12.5.6.2 | Solid Lipid Core Particles | 414 |
| 12.5.6.3 | Liposomes | 414 |
| 12.5.6.4 | Nanoparticles | 415 |
| 12.5.6.5 | Microspheres/Microparticles | 416 |
| 12.5.7 | Colon-Targeted Delivery Systems for Proteins and Peptides | 416 |
| 12.5.8 | Mucoadhesive Polymeric Systems and Stimuli-Responsive Hydrogels | 417 |
| 12.5.9 | Cell-Penetrating Peptides | 417 |
| 12.5.10 | Prodrug Approach | 417 |
| 12.6 | Clinical Application of Oral Protein Formulations | 418 |
| 12.7 | Case Studies of Oral Protein Formulations | 418 |
| 12.7.1 | Case Study I: Cyclosporine A | 418 |
| 12.7.2 | Case Study II: Oral Insulin | 421 |
| 12.7.3 | Case Study III: Prodrug Approach – Desmopressin | 422 |
| 12.8 | Conclusion | 422 |
| | References | 423 |

| | |
|--------------|------------|
| Index | 433 |
|--------------|------------|

Preface

Drug discovery and development is an outstandingly complex task. Technological innovations in biology, chemistry, and medicine have provided the pharmaceutical industry with a wealth of targets and molecules, with the potential to treat diseases formerly assumed intractable to drug therapy.

The consequential increase in complexity, both in terms of the molecules and their biological targets, combined with the increasing need to work in an efficient and cost-constrained environment has necessitated an evolution in the role of pharmaceutical sciences in discovery support.

Because more and more drug candidates in the pipeline pose constraints such as poor solubility and stability, the development of an overall formulation strategy to support *in vivo* studies should be considered carefully as it can reduce cycle time and resources.

The *in vivo* studies performed in the preclinical setting can broadly be classified as pharmacology, pharmacokinetic, and toxicology studies. The goals and challenges of these studies are diverse.

Therefore, drug developers must consider many aspects when positioning a preclinical drug candidate to succeed in first-in-human clinical trials.

Besides many other factors, a biopharmaceutical assessment of drug substances is crucial for different phases of the development process. In an early phase, pharmaceutical profiling should help to rate candidate molecules in terms of their “drug-like” properties.

The first step for a new molecule moving out of the discovery phase is the preformulation studies, or developability assessment. Indeed, preformulation work lays the foundation for choosing the right salt and polymorph, delivery technology, and formulation strategies.

Formulation approaches to deliver molecules in the preclinical setting include, besides many other innovative forms, the more traditional ones like suspensions, solutions, and amorphous dispersions administered as solids or in aqueous vehicles. Nowadays, advanced systems such as nanosuspensions and silica particles are also explored for this purpose.

The goals of preformulation studies are to choose the correct form of the drug substance, evaluate its physical and chemical properties, and generate a thorough understanding of the material's stability under the conditions that will lead to the development of a practical drug delivery system. Preformulation is a science that

serves as a big umbrella for the fingerprinting of a drug substance or product both at the early and later stages of development in pharmaceutical manufacturing.

Traditionally, pharmaceutical scientists participated in the discovery teams only in the later phases of lead development or in the lead optimization phase, and their role was largely to assess the development risks (developability) of the molecule advancing to clinical dosing.

These activities, while important, have been augmented to include early discovery formulation support related to building a basic understanding of biology through *in vivo* target validation and demonstration of proof of mechanism.

The book in hand, edited by a very experienced pharmaceutical scientist with many years of experience in this preformulation field, has pointed out with the selected chapters a comprehensive view of actual research filed in this area. In particular, the following chapters are enclosed:

- Impact of the polymorphic form of the drugs/NCEs on the preformulation and formulation development
- Regulatory aspects for formulation design – with focus on the solid state
- Effect of residual reactive impurities in excipients on the stability of pharmaceutical products
- Assessing pharmacokinetics of various dosage forms at early stage
- Preclinical safety assessment for excipients; oral, IV, and topical routes
- Preclinical formulation assessment of NCEs
- Strategies for the formulation development of poorly soluble drugs via oral route
- Physical characterization techniques to access amorphous nature
- Design and development of ocular formulations for preclinical and clinical trials
- Insights into innovative applications of parenteral formulations
- Transdermal medical devices: formulation aspects
- Formulation of therapeutic proteins: strategies for developing oral protein formulations

The series editors are confident that this book and the highly actual topics will provide valuable benefits to interdisciplinary drug discovery teams working in industry and academia. Last but not least, we thank Yogeshwar Bachhav for excellently editing this volume as well as Frank Weinreich and Stefanie Volk from Wiley-VCH for their valuable contributions to this project.

September 2018
Düsseldorf, FRG
Aachen, FRG
Boston, USA

Raimund Mannhold
Helmut Buschmann
Jörg Holenz

Impact of the Polymorphic Form of Drugs/NCEs on Preformulation and Formulation Development

MHD Bashir Alsirawan and Anant Paradkar

Center for Pharmaceutical Engineering Sciences, University of Bradford, Richmond Road, Bradford BD7 1DP, UK

1.1 Introduction

Polymorphism is a well-established phenomenon which describes the ability of a solid-state molecular structure to be repetitively positioned in at least two different arrangements in three-dimensional space. These different arrangements can result in different sets of physicochemical properties of the same molecular structure, which can significantly affect material behavior during handling, processing, and storing. Hence, polymorphism is crucial for many applications, including the pharmaceutical industry. Most drugs, whether already produced or newly discovered candidates, and usually referred to as new chemical entities (NCEs), are found as solids under normal conditions of temperature and pressure. Eighty-five percent of active pharmaceutical ingredients (APIs) display pseudopolymorphism, including 50% having real polymorphism [1]. In addition, Cruz-Cabeza et al. have listed polymorphic incidence of single-component NCEs from the Cambridge Structure Database (CSD), European Pharmacopeia, and data from the extensive screening procedures performed in Roche and Lilly (Table 1.1) [2].

Consequently, polymorphism must be taken into consideration during every processing stage starting from early steps such as preformulation and formulation development, passing through processing, manufacturing, and storage, and eventually until consumption in humans.

1.1.1 Background

Polymorphism has been discussed and investigated by many reports [3–7]. Moreover, several definitions were made depending on the researcher or the field of research; McCrone (1965) defined polymorphism thus: “Polymorph is a solid crystalline phase of a given compound resulting from the possibility of at least two different arrangements of the molecule of that compound in the solid state.” Buerger defined polymorphism of a crystal as “molecular arrangements having different properties.” The definition by Purojit and Venugopalan states it is the “ability of a substance to exist as two or more crystalline phases that have different

Table 1.1 Polymorphism incidence for single-component NCE from several data source.

| Source | Number of single NCEs | Polymorphism occurrence (%) |
|----------------------------|-----------------------|-----------------------------|
| CSD | 5941 | 37 |
| European Pharmacopeia 2004 | 598 | 42 |
| Roche | 68 | 53 |
| Lilly | 68 | 66 |

arrangements or conformations of the molecules in the crystal lattice” [3]. IUPAC defined the phase transition between polymorphs as the “reversible transition of a solid crystalline phase at a certain temperature and pressure (the inversion point) to another phase of the same chemical composition with a different crystal structure” [8]. Other definitions were similar to those previously mentioned, such as different crystal arrangements for the same chemical composition [9], or crystal systems of same elemental structure but with unlike unit cells [4]. Desiraju has debated the experimentality of McCrone’s definition depending on previous observations of polymorphism cases where coexistence of two polymorphs within the same crystal is found with no distinctive phase separation or, in other cases, where two structures are very similar with a barely identified difference (divergence). Desiraju has suggested setting criteria to differentiate whether two arrangements are genuine polymorphs or belong to the same solid phase [6].

The first reported polymorphism event was discovered with calcium carbonate in 1788 by Kalporoth. In 1832, benzamide was the first organic molecule the polymorphism of which was observed by Wöhler and Liebig [10]. The first crystal structure of polymorphic form determined by X-ray diffraction was for resorcinol in 1938 [11].

Although the term polymorphism seems specific, there is confusion around designating different structures as polymorphs. Moreover, reports follow different terminology rules depending on the fields of interest and background. To mitigate this confusion, other terms have arisen such as pseudopolymorphism or solvatomorphism. However, several reports do not encourage using these terms as it may create further confusion [7, 12].

1.1.2 Types of Polymorphism

If we stick to the pure definition of polymorphism and exclude chemically non-similar structures, there are two primary types of polymorphism, conformational and packing polymorphism.

1.1.2.1 Conformational Polymorphism

This type of polymorphism resulted in molecules having flexible moieties which, in turn, have rotatable bonding. The rotational movement of a single bond in the molecular structure leads to a symmetry change and produces a new

configuration, and, subsequently, a change in lattice packing [13]. A typical example of conformational polymorphism is ranitidine hydrochloride, which has two polymorphs, form 1 and form 2. Both phases are monoclinic, with the same space group but with only a difference in the conformation and disorder of nitroethenediamine moiety (Figure 1.1) [14]. Triamcinolone acetonide acetate, a drug commonly used for rheumatoid arthritis, exists in three polymorphic forms A, B, and C and a monohydrate; all these forms exhibit conformational variations (Figure 1.1) which result in different packing (Figure 1.2) [15].

Figure 1.1 Molecular structure of triamcinolone polymorphs A (light blue), B (red and green), C (orange), and MH (blue). Source: Bučar et al. 2015 [14] and Wang et al. 2017 [15]. Adapted with permission of ACS.





Figure 1.2 Lattice packing of triamcinolone acetonide acetate polymorphs. Source: Wang et al. 2017 [15]. Adapted with permission of ACS.

1.1.2.2 Packing Polymorphism

In this type, the configuration and bond orientation between two structures is identical, yet the arrangement and backing of this conformation in a three-dimensional structure is not similar. Most of the pharmaceutical materials have flexible moieties; thus, it is rare to observe packing polymorphism in the field. Donepezil, which is used in the palliative treatment of Alzheimer's disease, has two packing polymorphs, forms K and F. The conformation similarity of the two forms was investigated by superimposing their structure using Mercury 3.3, a 3D structure visualization and measurement program. Root-mean-square deviation (RMSD) was then calculated and found to be insignificant (0.0624 Å) supporting the identical confirmation (Figure 1.3) [16].

1.1.3 Thermodynamic-Based Classification of Polymorphism

Polymorphic interconversion is primarily governed by the thermodynamic state of the material, and as per thermodynamic rules, both temperature and pressure determine the thermodynamic stability of a certain polymorph. Polymorphism type depends on the nature of solid-phase transition with respect to temperature or pressure and can be divided into monotropic and enantiotropic (Figure 1.4). Understanding and identifying the transition nature of polymorphs is crucial for establishing optimum parameters for crystallization, screening [17], processing, and storage of active ingredients and excipients [18, 19].

1.1.3.1 Enantiotropic Polymorphism

In enantiotropic polymorphism, one polymorph (let us call it form I) is considered the most stable at a certain temperature and pressure, at which the other polymorph (form II) is not stable, usually called metastable. On the other hand, the metastable form II becomes stable when reaching different temperature or pressure zones or reaching transition temperature T_t or pressure P_t .




Figure 1.3 Superimposed view of donepezil form F (blue) and form K (red); (a) crystallographic A axis view, (b) 90° angle view where an axis is horizontally positioned, the packing of two polymorphs are translated (green double-headed arrows). However, (c) superimposed molecular structures show identical conformations, meaning that the two phases are packing polymorphs. Source: Part et al. 2016 [16]. Adapted with permission of American Chemical Society.




Figure 1.4 Phase energy versus temperature diagram for the (a) enantiotropic and (b) monotropic interconversion for two polymorphic phases FI and FII.

Simultaneously, the stable form I becomes metastable and a phase transition from form I to form II takes place. In some cases, a third polymorph (form III) is found and it has a third temperature or pressure zone, above specific transition temperature or pressure, where it becomes the most stable among others.

1.1.3.2 Monotropic Polymorphism

This type describes the case where one polymorph is considered the most stable in a wide range of temperatures reaching high transition levels, higher than the melting point of the other forms which are all considered to be metastable polymorphs under their melting point.

Two thermodynamic rules can be applied, which basically rely on thermal analysis to distinguish the type of polymorphism. These rules are heat of fusion and heat of transition, and may be referred to as Burger–Ramberger rules [20]. To describe these rules, let us propose two polymorphs form I and T_{FII} T_t form II, where form I is more stable under normal temperature or before heating. The heat of fusion rule states that if the polymorph with the higher melting point has lower fusion enthalpy compared to the other form, the relationship between the two polymorphs is enantiotropic. However, if the higher melting point form has higher enthalpy of fusion, the polymorphism is monotropic. In the case of the heat of transition rule, polymorphs I and II are monotropic if the transition from form II to I is exothermic; or enantiotropic if the transition from form I to II is endothermic. It should be noted that the interconversion is reversible in enantiotropic systems and irreversible in monotropic polymorphism [4].

Moreover, enantiotropic polymorphs have a defined transition temperature (Figure 1.3) and can be determined experimentally. Conversely, monotropic systems have no observable transition temperature, yet there is a theoretical transition point that can be calculated using the Bauer–Brandl equation (1.1):

$$T_{tr} = \frac{\Delta H_{m,I}^T - \Delta H_{m,II}^T}{\Delta H_{m,I}^T/T_{m,I} - \Delta H_{m,II}^T/T_{m,II}} \quad (1.1)$$

where $\Delta H_{m,I}^T$ and $\Delta H_{m,II}^T$ are the melting enthalpy of forms I and II, respectively, and $T_{m,I}$ and $T_{m,II}$ are the melting points of forms I and II, respectively.

1.1.4 Concomitant Polymorphism

Concomitant polymorphism describes the case where more than one solid phase displays simultaneous nucleation and crystal growth under the same conditions and within the same batch. The reason behind concomitant polymorphism is a struggle between kinetically and thermodynamically stable polymorphs [21]. In other words, the kinetic and thermodynamic phases have a slight free energy difference [22]. This event may occur momentarily as the kinetically stable phase could convert rapidly to the thermodynamically stable phase, and in most cases the event is temporary and not observed due to the polymorphic conversion with time, or after predisposition to water or solvent (recrystallization or dissolution) [21]. The appearance of concomitant polymorphism can depend on the nature of crystallization solvent, temperature, and solution concentration [23].

Concomitant polymorphism poses a challenge to preformulation scientists when controlling the formation of a specific and desired polymorph. Several cases of APIs which exhibit concomitant polymorphism have been reported. A concomitant polymorphism of methoxyflavone, a nonsteroidal anabolic flavone, was reported. Thermodynamically stable form A and kinetically form B have a negligible difference in lattice energies and appear simultaneously after crystallization (Figure 1.5). Form B can transform to form A under the influence of temperature [24]. The relative nucleation and crystal growth rate is a crucial factor in controlling polymorphic appearance; furthermore, higher growth rate will govern the presence of the phase at the end of crystallization. Two polymorphs of donepezil, forms I and II, can appear concomitantly. The nucleation rate of form I is slower than that of form II, yet crystal growth is




Figure 1.5 Concomitant polymorphism after crystallization of methoxyflavone form A (bulk shape) and form B (needle shape). Source: Gong et al. 2016 [24]. Adapted with permission of American Chemical Society.

higher in form I. As a result, form I appears at the beginning of the process followed by form II, which dominates its presence at the end of the process [16].

1.1.5 Debatable Polymorphism Cases

These types are considered by many researchers as imperfect or pseudopolymorphism. Unlike the known variations found in basic polymorphism, the structures under this category have variations within the chemical structure which results in a change in crystal confirmation of packing.

1.1.5.1 Tautomeric Polymorphism or Tautomerism

Tautomerism is a simultaneous interconversion of isomeric organic compounds resulting from proton transfer caused by the presence of strong electronegative atoms such as O or N. Tautomerism depends on the presence of weakly acidic functional groups such as amines, amides, ketones, and lactams. The transformations are classified as chemical reactions and primarily consist of interconverting pairs such as keto-enol, oxime-nitroso, amine-imine, amide-imidic acid, and lactam-lactim reaction (Figure 1.6).

Tautomerism transition occurs at solution or melt state, where the reaction is at equilibrium, while at solid state, the crystallization of different tautomers causes a unit cell structure producing polymorphs with tautomeric origin. Ranitidine hydrochloride form 2 is found to consist of a tautomeric mixture (50 : 50) of enamine and nitronic acid, which takes place in the nitroethenediamine group [26]. In addition, omeprazole tautomerism takes place in solution state with 5-methoxy–6-methoxy transition. However, in solid state, both tautomers exist continuously at the molecular level or as solid solution (Figure 1.7) [27].

1.1.5.2 Enantiomerism/Stereoisomerism

The concept describes structures having a similar composition of atoms and bonding; however, they differ in the three-dimensional arrangement or orientation of the atoms. This type of structural change is also considered a chemical reaction as it requires the deconstruction of a covalent bond to allow a new covalent bond to form, resulting in a configuration that is the mirror image of the first structure. Most organic molecules that comprise asymmetric or chiral carbon exhibit this phenomenon, and therefore are named chiral.




Figure 1.6 Examples of tautomeric reactions. Source: Braga et al. 2014 [25]. Adapted with permission of Bentham Science Publishers Ltd.




Figure 1.7 Tautomeric forms of omeprazole; 5-methoxy tautomer in form V (right), and 6-methoxy tautomer in form I (left). Source: Bhatt et al. 2007 [27]. Adapted with permission of Royal Society of Chemistry.




Figure 1.8 Enantiomerism of L-thalidomide and D-thalidomide.

Enantiomerism is a crucial property in the pharmaceutical and pharmacological fields, as nearly 50% of the drugs are chiral and 90% of them are marketed as racemate equimolar mixtures (containing both isomers). Moreover, different isomers exhibit different pharmacokinetic and pharmacodynamic properties. The advancement in chiral drug design has produced safer and more effective candidates [28]. One of the examples of chiral or enantiomeric drugs is thalidomide which displays two enantiomers, (*S*)-thalidomide and (*R*)-thalidomide (Figure 1.8). Thalidomide was used for motion sickness, but it turned out that L-isomer is teratogenic and the therapeutic activity comes from the D-isomer.

1.1.5.3 Pseudopolymorphism

The utilization of the term pseudopolymorphism supports part of the definition of polymorphism “having the same chemical composition” as it describes molecules with different crystal structures caused by the presence of a secondary

Figure 1.9 Representation of pseudopolymorphism events which involve the incorporation of a heterostructure within the crystal lattice compared to polymorphism.





Figure 1.10 Packing polymorphism of caffeine: glutaric acid cocrystal, (a) FI and (b) FII. Source: Trask et al. 2005 [33]. Adapted with permission of American Chemical Society.

heterostructure within the crystal lattice (e.g. water, solvent, coformer, etc.) (Figure 1.9) [12]. However, the U.S. Food and Drug Administration (FDA) still consider hydrates, solvates, cocrystals, and amorphous phase as polymorphs [29–31].

However, some of these forms such as cocrystals tend to be polymorphic with their own structure [32]. For example, caffeine: glutaric acid cocrystal displays enantiotropic packing polymorphism; stable FII and metastable FI (Figure 1.10) [33, 34].

1.2 Polymorphism Impact on Drug/Excipient Properties

Different molecular conformation or packing for a compound provides specific characteristics and hence it necessitates formulation to utilize certain handling,

processing, or storage procedures. These characteristics can be categorized as physicochemical or mechanical properties, which are described in detail further.

1.2.1 Physicochemical Properties

Physicochemical properties are related to both physical and chemical features of molecular structure (e.g. presence of hydrophobic/hydrophilic groups, inter- and intramolecular bonding, crystal structure, etc.). Physicochemical properties include melting point, density, hygroscopicity, refractive index, surface activity, crystal habit, color, physical stability, and performance properties. Later involve solubility, dissolution rate, and bioavailability (which are interrelated). These properties are further described in detail due to their importance in pharmaceutical development (see Section 2.3). The difference in melting points originates from the variation in molecular interaction and lattice energy among polymorphs. Refractive index can be defined as the ratio of light speed in a vacuum to the speed of light within the crystal at a certain wavelength and temperature. Anisotropic crystals obtain multiple refractive index values, and hence are called birefringent, whereas isotropic crystals obtain a single refractive index, and thus are called non-birefringent. Refractive index is mainly determined by crystal structure and molecular arrangements; therefore, different polymorphs will exhibit different refractive index and birefringence. This property can be detected by polarized light microscopy, and it is used to identify different polymorphs or phase transitions

Crystal color and shape are primarily dependent on the molecular conformation or packing in the crystal lattice which results in different macroscopic orientation within the crystal structure. Crystal color can be determined depending on how the light is absorbed and reflected by the crystal lattice, which changes according to lattice conformation [35, 36]. Crystal morphology is dictated by the crystal growth mechanism of crystal nuclei faces. Therefore, the growth of crystal nuclei having different crystal packing results in morphological variations. Triamcinolone exhibits three polymorphs and a monohydrate having different crystal shapes (Figure 1.11) [15]

Hygroscopicity is the measure of moisture uptake, sorption, and retention from the atmosphere (humidity), neighboring liquids (mostly water), or solids in contact. Both thermodynamic and kinetic factors are involved in this process. Hygroscopicity is a crucial property in pharmaceutical development as it has a direct impact on other properties such as solubility, dissolution rate, and stability [37]. Dynamic vapor sorption is a very popular technique in assessing the hygroscopicity of materials; it measures the mass change as a function of relative humidity level (RH, %) at isothermal conditions, called sorption isotherms [38]. Different polymorphs can show varied moisture uptake behavior. This can be attributed to the variation in lattice structure, intermolecular interactions, and positioning of hydrophilic/hydrophobic molecular arrangement. Dynamic vapor sorption analysis of amisulpride forms I and II (Figure 1.12) shows that moisture uptake by form II is lower compared to that of form I [39].